Dermata Therapeutics, Inc.
DRMA
$1.21
-$0.02-1.63%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.80M | 1.54M | 1.37M | 1.26M | 1.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.01M | 1.93M | 1.90M | 1.76M | 1.77M |
| Operating Income | -3.01M | -1.93M | -1.90M | -1.76M | -1.77M |
| Income Before Tax | -2.97M | -1.85M | -1.86M | -1.69M | -1.70M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.97M | -1.85M | -1.86M | -1.69M | -1.70M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.97M | -1.85M | -1.86M | -1.69M | -1.70M |
| EBIT | -3.01M | -1.93M | -1.90M | -1.76M | -1.77M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.74 | -0.48 | -1.65 | -1.65 | -1.66 |
| Normalized Basic EPS | -0.46 | -0.30 | -1.03 | -1.03 | -1.04 |
| EPS Diluted | -0.74 | -0.48 | -1.65 | -1.65 | -1.66 |
| Normalized Diluted EPS | -0.46 | -0.30 | -1.03 | -1.03 | -1.04 |
| Average Basic Shares Outstanding | 4.02M | 3.86M | 1.13M | 1.03M | 1.03M |
| Average Diluted Shares Outstanding | 4.02M | 3.86M | 1.13M | 1.03M | 1.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |